• News Ticker alerts

Shares of biotech Illumina are down 31.76% to $27.25 this morning (Oct. 7) and pressuring some other biotechs. The maker of DNA analysis equipment expects third quarter revenue of $235 million, down sharply from analysts' expectations of $278.3 million. One by one, analysts are revising their ratings of Illumina stock downward.

  • News Ticker alerts


Sign in to comment

Join our newsletter list for
$5 off your next purchase
on our daily deal site, ReaderCity.com